Activation of GPR40 as a Therapeutic Target for the Treatment of Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
The stimulation of insulin secretion by glucose can be modulated by multiple nutritive, hormonal, and pharmacological inputs. Fatty acids potentiate insulin secretion through the generation of intracellular signaling molecules and through the activation of cell surface receptors. The G-protein–coupled receptor 40 (GPR40), also known as free fatty acid receptor 1 (we will use GPR40 in this review), has emerged as an important component in the fatty acid augmentation of insulin secretion. By signaling predominantly through Gαq/11, GPR40 increases intracellular calcium and activates phospholipases to generate diacylglycerols resulting in increased insulin secretion. Synthetic small-molecule agonists of GPR40 enhance insulin secretion in a glucose-dependent manner in vitro and in vivo with a mechanism similar to that found with fatty acids. GPR40 agonists have shown efficacy in increasing insulin secretion and lowering blood glucose in rodent models of type 2 diabetes. Recent phase I and phase II clinical trials in humans have shown that the GPR40 agonist TAK-875 reduces fasting and postprandial blood glucose and lowers HbA1c with efficacy equal to that of the sulfonylurea glimepiride without inducing hypoglycemia or evidence of tachyphylaxis. These data suggest that targeting the GPR40 receptor can be a viable therapeutic option for the treatment of type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621
The Mitochondrial Carnitine Palmitoyltransferase System — From Concept to Molecular Analysis
McGarry, J. D., & Brown, N. F. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.00001.x · Cited by 1,616 · cited 1×
“Oxidation of fatty acids is not required for enhancement of insulin secretion as inhibition of carnitine palmatoyltransferase-1 (CPT-1), responsible for the import of fatty acids (6) into the mitochondria for oxidation, results in enhanced glucosestimulated insulin secretion in palmitatetreated cells.”
BackgroundFree fatty acids regulate insulin secretion from pancreatic β cells through GPR40
Itoh, Y., Kawamata, Y., Harada, M., Kobayashi, M., Fujii, R., Fukusumi, S., Ogi, K., Hosoya, M., Tanaka, Y., Uejima, H., et al. (2003) · Nature · doi:10.1038/nature01478 · Cited by 1,538 · cited 1×
“Subsequent studies from two groups identified free fatty acids as ligands for the GPR40 protein (16,17), and GPR40 shows higher affinity for longer-chain fatty acids with a half-maximal effective concentration (EC50) in the 1–2 mmol/L range (17,18).”
BackgroundPancreatic β Cell Dedifferentiation as a Mechanism of Diabetic β Cell Failure
Talchai, C., Xuan, S., Lin, H. V., Sussel, L., & Accili, D. (2012) · Cell · doi:10.1016/j.cell.2012.07.029 · Cited by 1,415
Kashyap, S., Belfort, R., Gastaldelli, A., Pratipanawatr, T., Berria, R., Pratipanawatr, W., Bajaj, M., Mandarino, L., DeFronzo, R., & Cusi, K. (2003) · Diabetes · doi:10.2337/diabetes.52.10.2461 · Cited by 503
A human cell surface receptor activated by free fatty acids and thiazolidinedione drugs
Kotarsky, K., Nilsson, N. E., Flodgren, E., Owman, C., & Olde, B. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)03064-4 · Cited by 352 · cited 1×
“Based on the original observation ofKotarsky (52) that some thiazolidinediones could activate surface receptors later identified as GPR40, Tan et al.”
BackgroundFujiwara, K., Maekawa, F., & Yada, T. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00035.2005 · Cited by 253
Burant, C. F., Viswanathan, P., Marcinak, J., Cao, C., Vakilynejad, M., Xie, B., & Leifke, E. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61879-5 · Cited by 244 · cited 1×
“Based on these favorable results, a 12week, double-blind, placebo-controlled phase II study was performed in type 2 diabetic subjects that compared daily administration of TAK-875 and glimepiride with placebo (54).”
BackgroundSelf-citationβ-cell failure as a complication of diabetes
Chang-Chen, K. J., Mullur, R., & Bernal-Mizrachi, E. (2008) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-008-9101-5 · Cited by 225 · cited 2×
“Is there a potential for adverse effects of prolonged stimulation of GPR40? Numerous studies in vivo and in vitro have shown that prolonged exposure to fatty acids, with or without elevated glucose, results in b-cell secretory defects and direct toxic effects that result in b-cell death (4).”
BackgroundSalehi, A., Flodgren, E., Nilsson, N. E., Jimenez-Feltstrom, J., Miyazaki, J., Owman, C., & Olde, B. (2005) · Cell and Tissue Research · doi:10.1007/s00441-005-0017-z · Cited by 150
Cited by
Miyamoto, J., Mizukure, T., Park, S.-B., Kishino, S., Kimura, I., Hirano, K., Bergamo, P., Rossi, M., Suzuki, T., Arita, M., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.610733 · Cited by 272
G Protein–Coupled Receptors Targeting Insulin Resistance, Obesity, and Type 2 Diabetes Mellitus
Riddy, D. M., Delerive, P., Summers, R. J., Sexton, P. M., & Langmead, C. J. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014373 · Cited by 108
“FFAR1 is a target of great therapeutic interest after the phase II clinical trial with fasiglifam (TAK-875), a FFAR1 agonist, yielded lowering of HbA1c without unwanted side effects, including hypoglycemia or tachyphylaxis (Burant, 2013).”
Multitarget PPARγ Agonists as Innovative Modulators of the Metabolic Syndrome
Ammazzalorso, A., Maccallini, C., Amoia, P., & Amoroso, R. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.04.030 · Cited by 39
Metadata
- Authors
- Burant, C. F.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-07-17
- Volume
- 36
- Issue
- Supplement_2
- Pages
- S175-S179
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2006474213
- Cited by
- 101
- References
- 10
- FWCI
- 9.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Activation of GPR40 as a Therapeutic Target for the Treatment of Type 2 Diabetes. https://app.cochat.ai/papers/10.2337/dcs13-2037
- The paper
- Burant, C. F. (2013). Activation of GPR40 as a Therapeutic Target for the Treatment of Type 2 Diabetes. Diabetes Care. https://doi.org/10.2337/dcs13-2037
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.